Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
Primedic
Ampronix

Special Glasses Help Surgeons Visualize Cancer

By HospiMedica International staff writers
Posted on 27 Feb 2014
Image: Breast surgeon Julie Margenthaler, MD, visualizing cancer cells (Photo courtesy of WUSTL - Washington University in St. Louis).
Image: Breast surgeon Julie Margenthaler, MD, visualizing cancer cells (Photo courtesy of WUSTL - Washington University in St. Louis).
High-tech glasses may help surgeons distinguish cancer cells from healthy cells by making them glow blue when viewed through the eyewear.

Developed by researchers at Washington University (St. Louis, MO, USA), the technology, called optical projection of acquired luminescence (OPAL), incorporates custom video technology, a head-mounted display, and a targeted molecular contrast agent that attaches to cancer cells, making them glow blue when irradiated with a special light. The resulting fluorescence intensity maps are projected onto the imaged surface and viewed through the glasses, rather than via wall-mounted display monitors.

To demonstrate the proof-of-principle for OPAL applications in oncologic surgery, lymphatic transport of indocyanine green was visualized in live mice for real-time identification of sentinel lymph nodes. Subsequently, peritoneal tumors in a murine model of breast cancer metastasis were identified using OPAL following systemic administration of a tumor-selective fluorescent molecular probe. The researchers noted that tumors as small as one mm in diameter could be detected. The study was published in the December 2013 issue of the Journal of Biomedical Optics.

“These initial results clearly show that OPAL can enhance adoption and ease-of-use of fluorescence imaging in oncologic procedures relative to existing state-of-the-art intraoperative imaging systems,” said lead author professor of radiology and biomedical engineering Samuel Achilefu, PhD. “This technology has great potential for patients and health-care professionals. Our goal is to make sure no cancer is left behind.”

“We’re in the early stages of this technology, and more development and testing will be done, but we’re certainly encouraged by the potential benefits to patients,” said associate professor of surgery Julie Margenthaler, MD, who performed the first in-human operation using the system at the WUSTL Barnes-Jewish Hospital (St. Louis, MO, USA) on February 10, 2014. “Imagine what it would mean if these glasses eliminated the need for follow-up surgery and the associated pain, inconvenience, and anxiety.”

Related Links:

Washington University
Barnes-Jewish Hospital



Armstrong Medical Industries
JD Honigberg International
Mercury Medical
DeRoyal

Channels

Critical Care

view channel

Uric Acid Boosts Thrombolytic Therapy in Stroke

A new study reveals that uric acid (UA) in conjunction with intravenous thrombolytic therapy in patients suffering an acute ischemic stroke could help improve outcomes, particularly in women. Researchers at the University of Barcelona (UB; Spain), the Sunyer Biomedical Research Institute (Barcelona, Spain), and other... Read more

Women's Health

view channel

Prenatal Testing Can Detect Cancer in Mothers

A new study suggests that noninvasive prenatal testing (NIPT) for genetic anomalies could identify occult, previously undiagnosed maternal malignancies. Researchers at Tufts University Medical Center (Boston, MA, USA), the Dana-Farber Cancer Institute (Boston, MA, USA), and other institutions analyzed 125,426 samples... Read more

Business

view channel

Stryker to Acquire Muka Metal in Cash Transaction

Stryker Corporation (Kalamazoo, MI, USA) has announced a definitive agreement to acquire Muka Metal (Kayseri, Turkey). Stryker and Muka Metal, a leading manufacturer and marketer of hospital beds, stretchers, and related patient room furniture and accessories, have maintained a business relationship under a distribution... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.